Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04494958 | Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer(PALBOBIN) | completed | Phase 1 / Phase 2 | 24 | Fundacion OncosurNETWORK | 1 | Mar 24, 2025 | clinicaltrials |
| NCT02684227 | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2025 |
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | completed | Phase 2 | 36 | Aprea TherapeuticsINDUSTRY | 3 | Mar 17, 2025 | clinicaltrials |
| NCT03149822 | Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 45 | University of Colorado, DenverOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04401800 | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | completed | Phase 2 | 64 | BeiGeneINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04710641 | Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone(OUTREACH2) | completed | Phase 2 | 8 | Mina Alpha LimitedINDUSTRY | 2 | Mar 6, 2025 | clinicaltrials |
| NCT01767636 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04297280 | TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma | completed | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT03250676 | Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | completed | Phase 1 / Phase 2 | 151 | Eisai Inc.INDUSTRY | 3 | Feb 25, 2025 | clinicaltrials |
| NCT04948697 | A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | completed | Phase 2 | 94 | BeiGeneINDUSTRY | 2 | Feb 24, 2025 | clinicaltrials |
| NCT01130519 | A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer | completed | Phase 2 | 83 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2025 | clinicaltrials |
| NCT02907099 | Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03092518 | Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05162352 | Donafenib Plus Sintilimab for Advanced HCC | completed | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03439891 | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 16 | Robin Kate KelleyOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03333915 | Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 128 | BeiGeneINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT04511455 | Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment | completed | Phase 2 | 22 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04522908 | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function | completed | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT02694809 | The PROMISE Study: Duavee in Women With DCIS | completed | Phase 2 | 142 | Northwestern UniversityOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04662112 | Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma(NASOX) | completed | Phase 1 / Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04767906 | Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors(CaPture) | completed | Phase 2 | 16 | University of LeipzigOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04499924 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer(MOUNTAINEER-02) | completed | Phase 2 / Phase 3 | 17 | Seagen Inc.INDUSTRY | 6 | Jan 22, 2025 | clinicaltrials |
| NCT06108596 | Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail(PICS) | completed | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT04535414 | Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers | completed | Phase 2 | 195 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2025 | clinicaltrials |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | completed | Phase 1 / Phase 2 | 132 | BioAtla, Inc.INDUSTRY | 6 | Jan 15, 2025 | clinicaltrials |
| NCT01884961 | Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2(IL2HD) | completed | Phase 2 | 46 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT02761057 | Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 2 | Jan 13, 2025 | clinicaltrials |
| NCT05031494 | A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers | completed | Phase 2 | 40 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 2 | Jan 6, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03535727 | A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04068831 | Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02993159 | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | completed | Phase 2 | 100 | Northwestern UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT03206203 | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | completed | Phase 2 | 106 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03370718 | Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02528643 | A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 165 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Dec 6, 2024 | clinicaltrials |
| NCT03009461 | Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis | completed | Phase 2 | 64 | Peking UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03487666 | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | completed | Phase 2 | 45 | Georgetown UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04701060 | Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | completed | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03436563 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT03043313 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | completed | Phase 2 | 117 | Seagen Inc.INDUSTRY | 5 | Nov 26, 2024 | clinicaltrials |
| NCT04111510 | Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 6 | Yale UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 24, 2025source: clinicaltrials